share_log

藥明合聯:於2024年6月12日舉行的股東週年大會之投票表決結果

WUXI XDC: POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 12, 2024

Hong Kong Stock Exchange ·  Jun 12 22:06
Summary by Futu AI
藥明合聯生物技術有限公司於2024年6月12日召開的股東週年大會上,所有提呈的決議案均獲得全數通過。這包括了接納截至2023年12月31日止年度的經審核財務報表、董事會報告及獨立核數師報告,以及重選李錦才博士、張靖偉先生及席曉捷先生為執行董事。此外,會議還通過了授權董事會釐定董事酬金、續聘德勤會計師行為核數師、批准2024年股份計劃及授權上限,並授予董事一般授權以發行、配發及處理公司股份。股東大會當日,公司已發行股份總數為1,198,104,069股,無股東就會上決議案投票受限,亦無股東表明反對或放棄投票。會議由執行董事兼首席執行官李錦才博士主持,並有其他董事成員出席。
藥明合聯生物技術有限公司於2024年6月12日召開的股東週年大會上,所有提呈的決議案均獲得全數通過。這包括了接納截至2023年12月31日止年度的經審核財務報表、董事會報告及獨立核數師報告,以及重選李錦才博士、張靖偉先生及席曉捷先生為執行董事。此外,會議還通過了授權董事會釐定董事酬金、續聘德勤會計師行為核數師、批准2024年股份計劃及授權上限,並授予董事一般授權以發行、配發及處理公司股份。股東大會當日,公司已發行股份總數為1,198,104,069股,無股東就會上決議案投票受限,亦無股東表明反對或放棄投票。會議由執行董事兼首席執行官李錦才博士主持,並有其他董事成員出席。
At the annual shareholders' meeting held on June 12, 2024, all proposed resolutions were passed in full. This includes accepting the audited financial statements, board of directors' report and independent auditor's report for the year ended December 31, 2023, as well as re-electing Dr. Li Jindong, Mr. Zhang Jingwei and Mr. Xi Xiaojie as executive directors. In addition, the meeting approved authorizing the board of directors to determine directors' remuneration, renew the appointment of Deloitte as the auditor, approve the 2024 share plan and authorize the limit, and grant general authority to directors to issue, allot and deal with the company's shares. On the day of the shareholders' meeting, the company had issued a total of 1,198,104,069 shares, and shareholders without shares were restricted from voting on resolutions, and no shareholders expressed opposition or abstained from voting. The meeting was chaired by Dr. Li Jindong, executive director and chief executive officer, and attended by other board members.
At the annual shareholders' meeting held on June 12, 2024, all proposed resolutions were passed in full. This includes accepting the audited financial statements, board of directors' report and independent auditor's report for the year ended December 31, 2023, as well as re-electing Dr. Li Jindong, Mr. Zhang Jingwei and Mr. Xi Xiaojie as executive directors. In addition, the meeting approved authorizing the board of directors to determine directors' remuneration, renew the appointment of Deloitte as the auditor, approve the 2024 share plan and authorize the limit, and grant general authority to directors to issue, allot and deal with the company's shares. On the day of the shareholders' meeting, the company had issued a total of 1,198,104,069 shares, and shareholders without shares were restricted from voting on resolutions, and no shareholders expressed opposition or abstained from voting. The meeting was chaired by Dr. Li Jindong, executive director and chief executive officer, and attended by other board members.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.